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Abstract
Background
Pericardial fluid (PF) contains several biologically active substances, which may provide
information regarding the cardiac conditions. Nitric oxide (NO) has been implicated in car-
diac remodeling. We hypothesized that L-arginine (L-Arg) precursor of NO-synthase (NOS)
and asymmetric dimethylarginine (ADMA), an inhibitor of NOS, are present in PF of cardiac
patients and their altered levels may contribute to altered cardiac morphology.
Methods
L-Arg and ADMA concentrations in plasma and PF, and echocardiographic parameters of
patients undergoing coronary artery bypass graft (CABG, n = 28) or valve replacement (VR,
n = 25) were determined.
Results
We have found LV hypertrophy in 35.7% of CABG, and 80% of VR patients. In all groups,
plasma and PF L-Arg levels were higher than that of ADMA. Plasma L-Arg level was higher in
CABG than VR (75.7±4.6 μmol/L vs. 58.1±4.9 μmol/L, p = 0.011), whereas PF ADMA level
was higher in VR than CABG (0.9±0.0 μmol/L vs. 0.7±0.0 μmol/L, p = 0.009). L-Arg/ADMA
ratio was lower in the VR than CABG (VRplasma: 76.1±6.6 vs. CABGplasma: 125.4±10.7,
p = 0.004; VRPF: 81.7±4.8 vs. CABGPF: 110.4±7.2, p = 0.009). There was a positive correla-
tion between plasma L-Arg and ADMA in CABG (r = 0.539, p = 0.015); and plasma and PF
L-Arg in CABG (r = 0.357, p = 0.031); and plasma and PF ADMA in VR (r = 0.529, p = 0.003);
and PF L-Arg and ADMA in both CABG and VR (CABG: r = 0.468, p = 0.006; VR: r = 0.371,
p = 0.034). The following echocardiographic parameters were higher in VR compared to
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CABG: interventricular septum (14.7±0.5 mm vs. 11.9±0.4 mm, p = 0.000); posterior wall
thickness (12.6±0.3 mm vs. 11.5±0.2 mm, p = 0.000); left ventricular (LV) mass (318.6±23.5
g vs. 234.6±12.3 g, p = 0.007); right ventricular (RV) (33.9±0.9 cm2 vs. 29.7±0.7 cm2, p =
0.004); right atrial (18.6±1.0 cm2 vs. 15.4±0.6 cm2, p = 0.020); left atrial (19.8±1.0 cm2 vs.
16.9±0.6 cm2, p = 0.033) areas. There was a positive correlation between plasma ADMA and
RV area (r = 0.453, p = 0.011); PF ADMA and end-diastolic (r = 0.434, p = 0.015) and systolic
diameter of LV (r = 0.487, p = 0.007); and negative correlation between PF ADMA and LV
ejection fraction (r = -0.445, p = 0.013) in VR.
Conclusion
We suggest that elevated levels of ADMA in the PF of patients indicate upregulated RAS
and reduced bioavailability of NO, which can contribute to the development of cardiac
hypertrophy and remodeling.
Introduction
The pericardium is a fluid filled double-layered sac that surrounds the heart and the proximal
ends of the large coronaries. The space between the two layers is filled with serous fluid, called
pericardial fluid (PF). One of the main physiological roles of the PF is providing a proper fric-
tion within the pericardium by lubricating the epicardial surface making possible the continu-
ous movement of the heart in every beat [1]. For many years PF was considered as a passive
ultrafiltrate of the plasma produced by hydrostatic pressure difference and osmotic concentra-
tion gradient between the plasma and the PF [2]. However, other studies using rabbits and
dogs extended this simplistic view by further analyzing the composition of the PF [3].
One of the first extensive studies obtained detailed information regarding the composition
of PF of 30 patients undergoing elective open heart surgery, and found that concentrations of
small molecules (such as urea, uric acid, glucose and electrolytes) were essentially the same in
both the PF and the plasma [4]. However, production of PF involves not only filtration pro-
cesses, but also active mechanisms resulting in the accumulation of several biologically impor-
tant substances, which are produced by the myocardium. Such substances are endothelins
(ETs) [5], adenine nucleosides [6], angiotensin [7]. It has also been revealed that these sub-
stances present in higher concentration in the PF compared to the plasma. An increased con-
centration of these substances has been reported during cardiac diseases [8]. In addition, the
composition of PF is altered in various cardiac diseases [9] and in cardiac hypertrophy [10].
Nevertheless, still relatively few studies are extant, which investigated the biochemical compo-
sition of PF to humans [11].
Nitric oxide (NO) is a multirole molecule, among others modulating vasomotor tone, and
attenuating tissue proliferation and growth [12]. Several studies have demonstrated the anti-
hypertrophic role of NO on cardiac muscle [13–15]. For instance, induced hypertrophied car-
diomyocytes were inhibited by administration of NO [16]. Also, reduced NO availability has
been associated with cardiac hypertrophy [17]. Previous studies established that asymmetric
dimethylarginine (ADMA), being a false substrate limits the activity of endothelial nitric oxide
(NO) synthase thus production of NO. In addition, our previous studies and others revealed
that elevated levels of ADMA elicits the release of reactive oxygen species (ROS) by activation
of the renin angiotensin system (RAS) leading to vascular dysfunction [18–20]. ADMA can
accumulate due to enhanced production or reduced catabolism and excretion [21]. ADMA
is produced by protein arginine methyltransferase type I (PRMT-1) via methylation from
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L-arginine (L-Arg) and mainly metabolized by dimethylarginine dimethyl-aminohydrolase
(DDAH) [22]. Furthermore, ADMA has been identified as a risk factor for endothelial dys-
function and was shown to accelerating the progression of several cardiovascular diseases [23].
Thus, ADMAmay serve as a biomarker indicating reduced bioavailability of NO [18–20]. Pre-
vious studies have shown that ADMA is partly excreted by the kidneys, and suggested that low
urinary ADMA level predicts impaired cardiac function [24]. It has been reported by several
studies that plasma levels of ADMA increase in chronic kidney disease (CKD) [25]. First, Val-
lance et al have shown a relationship in patients with chronic renal failure [25]. In addition,
studies have shown that elevated plasma ADMA levels are implicated with the progression of
chronic kidney disease (CKD) and increased the risk for cardiovascular disease [26, 27]. Pecchini
et al compared findings of ELISA and LC-MS/MSmethods regarding the measured level of
ADMA, and found that from the same sample ADMA values were higher measured by ELISA
compared to LC-MS/MS, however they concluded that ELISA overestimates ADMA concentra-
tion [28]. Also, Ronden et al showed that at increased concentration ADMA is excreted by the
kidneys, however when GFR declines its excretion is lower. Also, in the presence of CKD the
activity of PRMT increases with the consequent elevation in ADMA production, which could be
further increased by the decreased catabolism due to reduced DDAH enzyme activity [29].
Indeed, clinical studies showed an elevated plasma level of ADMA in aortic valve stenosis
[30] and revealed that ADMA is a predictor of heart diseases, such as acute coronary events
[31]. Many of these patients usually undergo coronary artery bypass graft (CABG) and valve
replacement (VR) surgeries.
Based on the aforementioned, we hypothesized that the level of ADMA in the PF may be
different in patients with CABG and VR, which could contribute to the morphological changes
of the heart. Thus, we measured the concentrations of ADMA in the PF obtained from patients
who underwent either coronary artery bypass graft or valve replacement surgery. Moreover, we
measured the levels of ADMA, and L-Arg in plasma of all groups, and in PF of CABG and VR
patients, and made comparisons between the different groups.
Methods
Study description and clinical characterization
In the present study, we have investigated 73 patients at the Heart Institute at the Medical
School, University of Pecs, Hungary. This is a cross-sectional investigation of 28 patients
undergoing coronary artery bypass graft (CABG) surgery, and 25 undergoing cardiothoracic
surgery for valve replacement (VR). We measured peripheral blood plasma level of ADMA in
20 non-cardiac patients (NCP). Written informed consent was obtained from all individuals
before participation in the study. The Ethics Committee of the Medical School of University of
Pecs (RKEB-4123/2011) approved the investigation and consent documents. The investigation
conforms to the principal outlined in the Declaration of Helsinki. Plasma was harvested from
NCP, and both plasma and PF were collected from the patients after median sternotomy and
collected into heparinized vacutainer tubes.
Echocardiography
All patients underwent complete 2-D transthoracic echocardiography before and after surgery.
Two-dimensional (2-D), M-mode and Doppler echocardiography with automated border
detection were performed using Hewlett-Packard Sonos 5500 echocardiograph with a 2.5 MHz
transducer (Hewlett-Packard, USA). 2-D echocardiographic measurements were performed
according to the recent European guidelines [32]. All echocardiographic measurements were
performed by the same (blinded for the patients conditions) cardiologist having an expert
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license in transthoracic echocardiography, which minimized the variability and bias in the
measurements. All the recorded images were analyzed off-line.
The following parameters were measured: left ventricular end-diastolic diameter (Dd), left
ventricular end-systolic diameter (Ds), thickness of interventricular septum (IVS) and poste-
rior wall (PW), right ventricular (RV), right atrial (RA), and left atrial (LA) area.
Biochemical analysis
We have followed the procedure as previously described in detail [33]. PF and blood samples
were centrifuged (3000 rpm, 30 min) immediately after collection. Supernatants were achieved
at -75°C until biochemical analysis. L-Arg and asymmetric dimethylarginine (ADMA) were
determined using liquid chromatography [34]. Quantification of ADMA and L-Arg derivatives
was performed at the Department of Applied Chemistry, University of Debrecen. The sample
preparation method and the chromatographic method were validated. Among other parame-
ters, the robustness of the chromatographic system, the recovery of the amino acids from the
samples and the repeatability have been checked. System suitability was also checked regularly
during the analysis of the samples. Solid phase extraction (SPE) of the analytes were performed
according to the method of Nonaka et al. [34]: 250 μL of plasma sample was mixed with 700 μL
of pH = 9.00 borate buffer and L-homoarginine hydrochloride (Sigma, HArg) was used as
internal standard (50 μL of 1000 μmol/L solution). The resulting mixture was passed through
OASIS MCX 3cc SPE cartridges at 750 mbar in a 12-column manifold (J. T. Baker). Thus, 11
samples and a standard solution were prepared parallel. The standard was used to check the
system suitability parameters, e.g. chromatographic resolution. Washing of the SPE cartriges
was done respectively by borate buffer, water, and methanol (Sigma). The analytes were eluted
with a mixture of concentrated aqueous ammonia (Reanal), water, and methanol with a vol-
ume ratio of 10/40/50. The solvent was evaporated beginning under nitrogen atmosphere and
finished in vacuum at 60°C. The dry residue was dissolved in 200 μL of ultrafiltered deionized
water (Millipore, Milli-Q) and derivatized according to Molnar-Perl et al. The samples
(200 μL) were mixed with 63 μL of reagent solution containing OPA (ortho-phthaldialdehyde
from Fluka) and MPA (3-mercaptopropionic acid from Aldrich) and incubated at RT for
10 min then cooled down to 5°C. For HPLC analysis, derivatized samples of 10 μL were
injected into a Waters 2695 Separations Module equipped with a thermostable autosampler
(5°C) and a column module (35°C). Separation was achieved with a Waters Symmetry SB C18
(4.6 x 150 mm, 3.5 μm) column and detected by a Waters 2745 Fluorescent detector (Waters
Milford, MA, USA). Gradient elution at a flow rate of 1 mL/min was applied during the analy-
sis with two mobile phases: A (20 mmol (NH4)2CO3 in water, pH = 7.50 ± 0.05) and B (aceto-
nitrile). The gradient program was as follows: 0–16 min: 91% A and 9% B, 16–17 min: linear
change to 70% A and 30% B and hold this for 5 minutes, 22–23 min: linear change to 91% A,
9% B and hold this for 12 minutes. The last two phases were to wash and regenerate the column
for the next sample. Arginine and homoarginine were detected at λex = 337 nm, λem = 520
nm, and λem = 454 nm was used for (ADMA) and symmetric dimethylarginine (SDMA).
Calculations and Statistical analysis
Left ventricular mass (LVM) was calculated using the American Society of Echocardiography
(ASE) convention: LV mass = 0.8 (1.04 ([LVIDD + PWTD + IVSTD]3- [LVIDD]3)) + 0.6 g [2].
The left ventricular ejection fraction (LVEF) as the index of global systolic function was calcu-
lated according to the Simpson formula [35]. GFR values were estimated using the six variable
modifications of diet in renal disease (MDRD) equation from creatinine levels, sex, race, and
age [36]. Serum creatinine was evaluated by the kinetic rate-blanked Jaffe compensated assay
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[37]. Results are expressed as mean±SEM. Statistical analyses were performed with Microsoft
Excel and SPSS. Statistically significant differences were determined using the Student’s two-
tailed unpaired t-test. The eGFR of each of the groups was compared using ANOVA on Ranks
analysis. The Pearson’s correlation test and linear regression analysis were used to calculate
correlations between levels of L-Arg and ADMA, and levels of ADMA and echocardiographic
parameters. p< 0.05 was considered as statistically difference.
Results and Discussion
Characteristics of patients
Descriptive statistics of NCP and patients with CABG or VR surgery are summarized in
Table 1, which shows the major demographic and clinical characteristics, as well as concomi-
tant risk factors and medications of patients. The mean ages and gender of both CABG and VR
patients were similar. 35.7% of CABG and 80% of VR patients demonstrated LV hypertrophy.
In general, the CABG patients had hypertension and most of them had a history of previous
acute myocardial infarction (AMI). The serum creatinine (sCr), and eGFR were similar in both
CABG and VR patients, albeit both patient groups mean eGFR indicate CKD stage 3. Pre-oper-
ative medications of the patients were similar, however patients of the CABG were treated with
higher dose of aspirin and statin before surgery compared to patients of the VR patients. In this
study, 53 Caucasian patients underwent cardiothoracic surgery: 28 for CABG, and 25 for VR.
CABG surgical interventions were as follows: x1 CABG-0; x2 CABG-3; x3 CABG-16; x4
CABG-8; x5 CABG-1. VR surgical interventions were as follows: AVR-17; MVR-7;
AVR-MVR-1. The types of surgery are summarized in Table 2.
L-arginine and ADMA levels in NCP, CABG, and VR patients
There was no significant difference in plasma levels of L-Arg and ADMA between the NCP,
and the patients undergoing open-heart surgery (L-ArgNCP: 70.8±6.0 μmol/L vs. L-ArgCABG:
75.7±4.6 μmol/L, p = 0.513; L-ArgNCP: 70.8±6.0 μmol/L vs L-ArgVR: 58.1±4.9 μmol/L,
p = 0.106; ADMANCP: 0.8±0.0 μmol/L vs. ADMACABG: 0.7±0.0 μmol/L, p = 0.144; ADMANCP:
0.8±0.0 μmol/L vs. ADMAVR: 0.8±0.0 μmol/L, p = 1.707) (Fig 1A and 1B). In CABG patients,
the plasma L-Arg levels were significantly higher compared to the VR patients (75.7±4.6 μmol/
L vs. 58.1±4.9 μmol/L, p = 0.011), whereas there was no significant difference in pericardial
fluid L-Arg levels between the CABG and the VR patients (76.9±4.4 μmol/L vs. 74.8±0.0 μmol/
L, p = 0.748) (Fig 1A). VR patients exhibited significantly higher ADMA levels in PF than that
of CABG group (0.9±0.0 μmol/L vs. 0.7±0.0 μmol/L, p = 0.009; Fig 1B). There was a significant
difference in L-Arg/ADMA ratio in plasma between the NCP and CABG patients (94.2±9.5 vs.
125.4±10.7, p = 0.044), but not between NCP and VR patients (94.2±9.5 vs. 78.3±7.7,
p = 0.197) (Fig 1C). Furthermore, the L-Arg/ADMA ratio both in plasma and PF was signifi-
cantly higher in the CABG compared to the VR patients (in plasma: 125.4±10.7 vs. 76.1±6.6,
p = 0.004, in PF: 110.4±7.2 vs. 81.7±4.8, p = 0.009; Fig 1C). We found a significant inverse cor-
relation between plasma L-Arg and eGFR in the CABG group (r = -0.367, p = 0.027). We
found no significant correlation between the L-Arg/ADMA ratio and eGFR neither in plasma
nor in PF of VR patients (pl L-Arg/ADMA ratio vs. eGFR: r = 0.200, p = 0.169; PF L-Arg/
ADMA ratio vs. eGFR: r = 0.073, p = 0.128).
Correlation between the levels of L-Arg and ADMA in plasma and PF
In NCP, there was no significant correlation between the levels of L-Arg and ADMA in plasma.
However, we found positive significant correlation between levels of pl L-Arg and ADMA in
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CABG patients (Fig 2A), and between PF L-Arg and ADMA in both CABG and VR patients
(Fig 2B). Furthermore, we found correlation between L-Arg levels of plasma and PF in CABG
patients (Fig 2C), and ADMA levels of plasma and PF in VR patients (Fig 2D). However, we
Table 1. Characteristics of the patients andmedications.
Variable NCP (n = 20) CABG (n = 28) VR (n = 25) p
Pre-operative data
Age (year) 42.0±3.5 59.7±1.5 56.4±4.1 0.331
Sex (male/female) 11/9 17/11 15/10 0.870
Hypertension* - 27 18 0.013
Cardiac hypertrophy - 0 19 0.001
Diabetes mellitus - 9 5 0.326
Previous AMI - 12 0 0.000
sCr (μmol/L) 74.0±5.4 78.8±6.9 75.0±3.6 0.649
Estimated GFR (ml/min/1.73m2) - 58.54±1.3 58.64±0.8 0.947
Pre-operative medication 85% in combination/15% in monotherapy# 75% in combination/25% in monotherapy#
Beta-blocker - 23 18 0.809
Ca-channel blocker - 8 5 0.671
ACE-inhibitor - 14 16 0.129
AT-receptor blocker - 4 1 0.208
Nitrate - 0 0 0.000
Aspirin - 21 4 0.000
Anti-diabetic - 7 3 0.561
Statin - 25 9 0.000
Diuretic - 11 6 0.242
Data are mean ± SEM.
*indicating blood pressure of 140/90 was considered normal in both cardiac groups [63].
#indicating medications in monotherapy for CABG (using beta-blocker or ACE inhibitor) and VR (using diuretic or ACE inhibitor).
CABG: coronary artery bypass graft; VR: valve replacement; AMI: acute myocardial infarction, Estimated GFR: estimated GFR calculated by the
Modification of Diet in Renal Disease (MDRD) GFR, sCr: serum creatitine, NCP–non-cardiac patients; CABG–coronary artery bypass graft; VR–valve
replacement.
doi:10.1371/journal.pone.0135498.t001
Table 2. Types of surgery operation.
Operation
CABGx1 0
CABGx2 3
CABGx3 16
CABGx4 8
CABGx5 1
AVR 17
MVR 7
AVR+MVR 1
Total 53
CABG: coronary artery bypass graft (the number indicates the vessels involved); VR: valve replacement;
AMI: acute myocardial infarction.
doi:10.1371/journal.pone.0135498.t002
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did not find correlation neither between the pl L-Arg and PF ADMA, nor between the PF
L-Arg and pl ADMA in CABG and in VR group, respectively.
Echocardiographic parameters of CABG and VR patients
As Fig 3 demonstrates, the thickness of interventricular septum (IVS), posterior wall of left
ventricle (PW) and right ventricular (RV), and right atrial (RA) and left atrial (LA) areas
Fig 1. L-Arg and asymmetric dimethylarginine (ADMA) in plasma of non-cardiac patients (NCP) (n = 20), and in plasma and pericardial fluid (PF) of
patients undergoing coronary artery bypass graft (CABG, n = 28) or valve replacement (VR, n = 25) surgery. (A) Levels of L-Arg in plasma and PF. (B)
Levels of ADMA in plasma and PF. (C) ratios of L-Arg and ADMA in plasma and PF. Mean ±SEM. * indicates significant (p<0.05) differences between CABG
and VR patients. Substrate availability indicated by the ratio, which is significantly increased in CABG compared to NCP and VR.
doi:10.1371/journal.pone.0135498.g001
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were significantly greater in VR patients than that of CABG patients (IVS: 14.7±0.5 mm vs.
11.8±0.4 mm, p = 0.000; PW: 12.8±0.3 mm vs. 11.5±0.2 mm, p = 0.000; RV: 33.7±1.0 cm2 vs.
29.9±0.7 cm2, p = 0.004; RA: 18.5±1.1 cm2 vs. 15.5±0.7 mm2, p = 0.020; LA: 19.6±1.0 cm2 vs.
17.1±0.6 cm2, p = 0.033). (Fig 3A and 3B). Also, LVM was significantly higher in VR patients
compared to CABG patients (318.9±19.3 g vs. 238.1±14.5 g, p = 0.007) (Fig 3C), whereas left
Fig 2. Correlations between the levels of L-Arg and asymmetric dimethylarginine (ADMA) in plasma and pericardial fluid (PF) of patients
undergoing coronary artery bypass graft or valve replacement surgery. (A) plasma L-Arg vs. ADMA of CABG patients (y = 0.006x + 0.21, r = 0.539,
p = 0.002); (B) PF L-Arg vs. ADMA of CABG and VR patients (CABG: y = 0.005x + 0.39, r = 0.468, p = 0.006; VR: y = 0.003x + 0.67, r = 0.371, p = 0.034); (C)
plasma vs. PF L-Arg of CABG patients (y = 0.347x + 50.69, r = 0.357, p = 0.031); (D) plasma vs. PF ADMA of VR patients (y = 0.498x + 0.50, r = 0.529,
p = 0.003).
doi:10.1371/journal.pone.0135498.g002
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ventricular ejection fraction (LVEF) was significantly higher in CABG as compared to VR
patients (CABG: 54.6±1.4% vs. VR: 59.5±1.5%, p = 0.05).
Correlation between the levels of ADMA and echocardiographic
parameters
We found positive correlation between the ADMA levels of plasma and RV area (r = 0.453,
p = 0.011; Fig 4A), PF ADMA and Ds of LV (r = 0.487, p = 0.007; Fig 4B), and Dd of LV (r = 0.434,
Fig 3. Morphological parameters of ventricles and atria of patients undergoing coronary artery bypass graft (CABG, n = 28) or valve replacement
(VR, n = 25) surgery. (A) The thickness of interventricular septum (IVS) and posterior wall (PW), (B) the right ventricular (RV), the right atrial (RA) and the left
atrial (LA) areas and (C) the left ventricular mass significantly higher in VR compared to CABG. Mean±SEM. p<0.05.
doi:10.1371/journal.pone.0135498.g003
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p = 0.015; Fig 4C) in VR patients. Furthermore, we found negative correlation between ADMA lev-
els of pericardial fluid and LVEF in VR patients (r = -0.445, p = 0.013; Fig 4D), but not in CABG
patients. However, we did not find correlations between ADMA levels of plasma and pericardial
fluid with other echocardiographic parameters, neither in CABG nor in VR patients (Table 3).
The salient findings of the present study are that
Fig 4. Correlations between the levels of asymmetric dimethylarginine (ADMA) and echocardiographic parameters of patients undergoing valve
replacement (VR) surgery. (A) plasma ADMA vs. area of right ventricle (y = 10.438x + 25.49, r = 0.453, p = 0.011); (B) PF ADMA vs. left ventricular (LV)
end-systolic diameter (y = 23.689x + 13.53, r = 0.487, p = 0.007); (C) PF ADMA vs. LV end-diastolic diameter (y = 20.531x + 34.72, r = 0.434, p = 0.015); D:
PF ADMA vs. LV ejection fraction (y = -16.779x + 73.55, r = -0.445, p = 0.013).
doi:10.1371/journal.pone.0135498.g004
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• L-Arg and its methylated derivative ADMA are present in the pericardial fluid (PF) of
patients undergoing coronary artery bypass graft (CABG) and valve replacement (VR)
surgeries,
• in CABG patients, plasma L-Arg concentration was higher compared to that of VR patients,
whereas in VR patients, PF ADMA concentration was higher compared to that of CABG
patients,
• we have found positive correlation between plasma L-Arg and ADMA levels in CABG
patients, between pericardial fluid L-Arg and ADMA levels in both CABG and VR patients,
between plasma L-Arg and pericardial fluid L-Arg levels in CABG patients, and between
plasma and pericardial fluid ADMA in VR patients,
• the L-Arg/ADMA ratio was smaller in the PF and plasma of VR than in CABG patients,
• we have found positive correlation between plasma ADMA levels and area of right ventricle,
between pericardial fluid ADMA levels and end-systolic, and end-diastolic diameter of the
left ventricle, and negative correlation between pericardial fluid ADMA levels and left ven-
tricular ejection fraction in VR patients.
Human PF contains bioactive substances and biomarkers
Previous studies have demonstrated that human PF contains bioactive substances, among
them some of which are vasoactive, such as endothelin 1 (ET 1) [5]. Also, it has been reported
that the level of these substances varies in different cardiac diseases [9, 38]. Furthermore, it has
Table 3. Correlations between ADMA levels and echocardiographic parameters of patients undergoing VR surgery.
ADMA levels vs. echocardiographic parameters R R2 p
Plasma ADMA vs RV 0.453 0.206 0.011
PF ADMA vs RV 0.132 0.017 0.265
Plasma ADMA vs IVS 0.123 0.015 0.279
PF ADMA vs IVS 0.137 0.019 0.257
Plasma ADMA vs PW -0.114 0.013 0.294
PF ADMA vs PW 0.176 0.031 0.200
Plasma ADMA vs Dd of LV 0.162 0.026 0.220
PF ADMA vs Dd of LV 0.434 0.189 0.015
Plasma ADMA vs Ds of LV 0.163 0.027 0.218
PF ADMA vs Ds of LV 0.487 0.237 0.007
Plasma ADMA vs RA 0.175 0.031 0.201
PF ADMA vs RA 0.050 0.003 0.406
Plasma ADMA vs LA 0.183 0.033 0.191
PF ADMA vs LA 0.104 0.011 0.310
Plasma ADMA vs LVM -0.018 0.000 0.466
PF ADMA vs LVM 0.201 0.040 0.168
Plasma ADMA vs LVEF -0.238 0.057 0.126
PF ADMA vs LVEF -0.445 0.198 0.013
ADMA: asymmetric dimethylarginine; PF: pericardial fluid; VR: valve replacement; RV: area of right ventricle; IVS: thickness of interventricular septum;
PW: thickness of posterior wall; Ds of LV: end-systolic diameter of left ventricle; Dd of LV: end-diastolic diameter of left ventricle; RA: area of right atria;
LA: area of left atria; LVM: left ventricular mass; LVEF: left ventricular ejection fraction; R: Pearson’s correlation coefficient; R2: R-squared value.
doi:10.1371/journal.pone.0135498.t003
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been revealed that in cardiac patients, certain bioactive substances, such as ET 1 present in
higher concentration in PF compared to the plasma [39]. Recently, a false substrate for NOS,
ADMA, which is a methylated derivative of L-Arg produced by PRMT1 and degraded by
dimethylarginine-dimethylamino-hydrolase (DDAH), has gained attention.
ADMA has been noted as a cardiovascular risk factor due to its increased plasma levels in
several cardiovascular diseases [40]. Furthermore, it has been demonstrated that ADMA
impairs NO-regulation of vascular tone in part, by direct inhibition of endothelial NO synthase
(eNOS) and by reducing bioavailability of NO by increased production of reactive oxygen spe-
cies (ROS) due to activation of the vascular renin-angiotensin system as shown in isolated arte-
rial vessels in vitro [18–20].
Human PF contains a high levels of ADMA
In the present study, we found that PF of patients undergoing CABG and VR contains L-Arg
and ADMA (Fig 1). There are studies reporting values between 50 and 100 μmol/L for L-Arg,
and 0.3–0.8 μmol/L for ADMA in humans [41–43]. The values of the plasma levels of L-Arg,
and ADMA of NCP obtained in this study fell into this range. Because, PF of healthy people
has not yet been investigated, therefore there are no exact reference values are available for con-
centrations of L-Arg and ADMA in PF in healthy individuals.
Importantly, the level of ADMA has been found to be elevated in various cardiovascular dis-
eases [31, 44–46]. Also, it has been demonstrated, that plasma level of ADMA changed after
stent placement in patients with coronary artery disease (CAD) [47]. Furthermore, Lu et al
showed that plasma ADMA level significantly correlated with the severity of CAD [48]. We
found that both plasma and PF levels of L-Arg was about 100 fold higher than that of ADMA
in both CABG and VR patients. Furthermore, in CABG patients and VR patients we observed
that plasma ADMA was near normal or reached the upper limit of the normal range. In VR
patients, we observed that the levels of PF ADMA were significantly higher as compared to the
CABG patients (Fig 1B).
L-Arg/ADMA ratio in plasma and PF as an indicator of NO bioavailability
Previous studies have suggested that L-Arg/ADMA ratio reflects NO bioavailability [36, 49]. It is
known that a sufficient amount of the substrate, L-Arg is necessary for NOS to produce NO.
However, ADMA in pathophysiological relevant concentrations–being a false substrate—is a
competitive inhibitor of eNOS, thus inhibits NO formation resulting in reduced NO synthesis
[18–20]. It has been shown that the L-Arg/ADMA ratio in plasma is about 100:1 in healthy indi-
viduals [34, 50]. Previously, it has been established that low L-Arg/ADMA ratio in acute myocar-
dial infarction (AMI) can be linked to the severity of coronary insufficiency [51]. Also, it was
previously reported that there is a correlation between coronary atherosclerotic score and plasma
L-Arg/ADMA ratio indicating that changes in this ratio is linked to the severity of CAD [48]. In
the present study, we found no significant difference in plasma L-Arg/ADMA ratio between the
NCP, and the CABG and VR patients, whereas both the plasma and PF L-Arg/ADMA ratios
showed a significant difference between the CABG and VR patients (Fig 1C).
We have found that both in CABG and VR patients eGFR was similar,<60ml/min/1.73 m2
(Table 1), suggesting the presence of renal insufficiency (because it has been defined as
GFR< 75 ml/min/1.73 m2) which is known to be strongly associated with heart diseases
[52, 53]. Also, we found a significant inverse correlation between plasma L-Arg and eGFR in
the CABG group, which is may be due to the higher L-Arg levels in the plasma of CABG
patients, which could be due to the higher L-Arg levels in CABG patients [24]. Previous studies
have shown that reduced L-Arg/ADMA ratio is associated with reduced GFR in patients with
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CKD [36] and that the kidneys releases L-Arg into the plasma, which may increase plasma
level L-Arg [54]. However, we have found no significant correlation between L-Arg/ADMA
ratio and eGFR of VR and CABG patients, suggesting that the primary reason for this is not
related to the kidney dysfunction. Different levels of ADMA in CABG and VR patients indicate
that ADMAmay have specific roles in the pathomechanisms of cardiac events and reflects vari-
ous pathological events of the heart. Taken together, these suggest that ADMAmay reflect the
pathophysiological and-morphological changes of the myocardium.
ADMA in PF and left ventricular remodeling/hypertrophy
Left ventricular hypertrophy is the result of interaction between a chronic hemodynamic over-
load and non-hemodynamic factors [55]. The diastolic dysfunction of the heart is known to be
the first predictor of left ventricular failure [56]. In the present study, the majority of VR patients
suffered from aortic stenosis, which caused significant chronic pressure overload of the left ven-
tricle [57]. We found, that echocardiographic parameters, which are characteristics of left ventric-
ular hypertrophy, such as thickness of IVS, and parameter of LVM increased significantly in VR
patients compared to CABG patients (Fig 3A and 3C). In the VR patients, areas of LA, RA and
parameter of RV area exhibited significant increase in comparison of CABG patients (Fig 3B).
The role of NO in the development of hypertrophy and remodeling of the cardiac muscle in
response to chronic changes in mechanical constraints (i.e., volume or pressure overload) is
important, because altered morphology of the heart affects contractile performance [13]. There
are several lines of evidence presented in previous decades suggesting that presence of adequate
level of NO limits the hypertrophic growth of the myocardium [15]. One of the mechanisms
that may explain the association between ADMA and cardiovascular disease is the ADMA-
induced cardiac hypertrophy. Several alternative mechanisms have also been proposed to
explain the association between ADMA and cardiac hypertrophy [58]. In cardiac myocytes in
cell culture, it has been demonstrated that ADMA can activate fibroblast growth factors recep-
tors. This can lead to myocardial hypertrophy and fibrosis, or induce excessive local activation
of the renin-angiotensin mechanism [59].
Normal level of NO and activity of NOS are essential for the prevention of heart remodeling,
therefore decreased NO availability may lead to a loss of such protection. In Fig 5, we have
summarized the potential mechanism of action of ADMA in modulation cardiac morphology.
We recently proposed a potential mechanism by which increased serum ADMA reduces the
bioavailability of NO [47]. Previously we have also shown that elevated levels of ADMA can
activate the renin-angiotensin system in the arteriolar wall. This can elicit increased production
of Ang II, which then activates NAD(P)H oxidase leading to increased levels of reactive oxygen
species interfering with the bioavailability of NO [19]. The activation of RAS increases the level
of Ang II, which is known to be a growth hormone [60]. These observations are in concordance
with previous studies and suggest that reduced level of NO [16] and increase activation of local
RAS [61] together promote cardiac hypertrophy (Fig 4). Elevated level of ADMA in the peri-
cardial fluid of patients in the VR patients correlates with left ventricular remodeling/hypertro-
phy and thus it can serve as a biomarker (Fig 5).
ADMA in the pericardial fluid
PF has been considered as a passive ultrafiltrate of the blood plasma resulting by hydrostatic
pressure difference between the plasma and PF and osmotic concentration gradient, as well [3].
It has also been shown that some substances in PF are derived from the cardiac interstitium,
such as adenine nucleosides [6] and other cardiac biomarkers [62]. In the present study, we
found that L-Arg levels both in the plasma and pericardial fluid obtained from CABG and VR
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Fig 5. Proposedmechanisms by which elevated level of ADMA in pericardial fluid elicits hypertrophy/remodeling of cardiac muscle: accordingly,
reduced NO bioavailability and increased level of Ang II together leads to development of cardiac hypertrophy/remodeling. ADMA–asymmetric
dimethylarginine, NO–nitric oxide, NOS–endothelial NO synthase, RAS–renin-angiotensin-system, Ang II–angiotensin II, ROS–reactive oxygen species.
doi:10.1371/journal.pone.0135498.g005
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patients were in the normal range (Fig 1A), whereas, ADMA levels reached the maximum of
the normal range in these patients (Fig 1B).
The positive correlation between plasma L-Arg and ADMA in CABG patients (Fig 2A) sug-
gests that pericardial ADMAmay originate from the plasma. However, as the slope of the
curve shows, pericardial ADMAmay originate not only from the plasma, but also from cardiac
tissues. Both in CABG and in VR patients, we observed significant positive correlations
between L-Arg and ADMA in pericardial fluid (Fig 2), suggesting that ADMA can be formed
in PF from L-Arg, but in different compartments, as slopes of the lines are different. Taken
together, these suggest that pericardial fluid ADMA in part origins from cardiac tissues and
more amount of ADMA is formed in VR than in CABG patients. Interestingly, in VR patients
we did not find correlation between plasma L-Arg and plasma ADMA, and between plasma
L-Arg and pericardial fluid ADMA. In our interpretation, these suggest that in VR patients
ADMAmay be generated in cardiac tissues from L-Arg, not just from plasma L-Arg. Although,
the positive correlation between pericardial L-Arg and ADMA (Fig 2B), and between plasma
and pericardial fluid ADMA suggest that in PF ADMA is metabolized from the pericardial
fluid L-Arg, however this correlation is not proportional. This latter findings and the positive
correlation between plasma and pericardial fluid ADMA (Fig 4D) indicate that ADMA–which
is produced and eliminated by several similar metabolic pathways in PF and plasma—may dif-
fuses between the two compartments.
Conclusions
In conclusion, based on present and previous findings, we suggest that elevated levels of asym-
metric dimethyl-arginine (ADMA) in the pericardial fluid of cardiac patients could indicate
important pathophysiological mechanisms, such as absolute or relative cardiac ischemia and
hypoxia leading to reduced bioavailability of nitric oxide, which–together with the locally
released growth hormone Ang II—can contribute to the development of cardiac hypertrophy
and remodeling (Fig 5). We propose that analyzing of pericardial fluid could be a valuable diag-
nostic tool, whereas interfering with the contents and effects of pericardial fluid open up new
therapeutic options to beneficially modify cardiac function and structure.
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